Corporate Governance
Hyloris attaches great value to good corporate governance and is aware that good governance is an important factor for all stakeholders.
The Company is administered by a Board of Directors and run by an Executive Committee, whose respective functions and responsibilities are clearly defined in the Corporate Governance Charter.
The General Meeting of Shareholders is convened once a year, on the second Tuesday of June at 2:00 pm CET, for its Ordinary meeting. A General Meeting of Shareholders may also be called in Special or Extraordinary circumstances whenever the Company interests dictate. Rules relating to General Meetings and main rights and obligations of Shareholders are further detailed in the Corporate Governance Charter.
The Audit Committee
The Audit Committee assists the Board in its responsibility of monitoring the management of Hyloris
Three members (67% independent):
-
- Marc Foidart (Chairman and Independent Director)
- James Gale (Independent Director)
- Stefan Yee (Non-executive Director)
The Remuneration and Nomination Committee
The Remuneration and Nomination Committee ensures that the appointment and remuneration process of Directors and Executive Management is organised objectively and professionally and proposes the remuneration policy for non-executive Directors and executive managers
Three members (67% independent):
-
- Stefan Yee (Chairman and Non-Executive Director)
- Carolyn Myers (Independent Director)
- Marc Foidart (Independent Director)
Board of Directors
Stefan Yee
CHAIRMAN and NON – EXECUTIVE DIRECTOR
the University of Chicago (as a BAEF Fellow).
Stijn Van Rompay
CHIEF EXECUTIVE OFFICER and CO-FOUNDER
Stijn co-founded and was the CEO of Alter Pharma, a high-growth pharmaceutical company focused on the development of complex generics and pharmacy-related product sales. He was also co-CEO of Uteron Pharma, a company focused on innovative female healthcare products.
Prior to these positions, Stijn was CFO and later, CEO of Docpharma (formerly quoted on Euronext Brussels) a generics and medical-device company. Under his leadership, the companies recorded strong growth and value creation. He also holds several non-executive director positions in the biotech sector, and acts as an advisor to venture capital investors. Stijn holds a Master’s degree in Applied Economics from the University of Antwerp.
Thomas Jacobsen
EXECUTIVE DIRECTOR and CO-FOUNDER
Leon Van Rompay
NON – EXECUTIVE DIRECTOR
Leon Van Rompay has more than 40 years’ experience in the pharmaceutical market. During his professional career he served in several positions including country & area manager (covering major territories) and board member of the Zambon Group. He was founder and CEO of Docpharma, a Belgian based generics company that was listed on Euronext and served on different boards including Ecodis and Uteron Pharmaceuticals. He was a founding member of BIGE/IBES (Belgian Institute for Health and Economics), the B.G.A. (Belgian Generic Association), BAPIE (Belgian Association of Parallel Import and Export) and was an executive committee member and board member of the Belgian Pharmaceutical Industry Association. He also was a member of the pharmaceutical deontological commission and responsible for this commission in the industry association executive committee
Marc Foidart
INDEPENDENT DIRECTOR
Marc Foidart obtained a Master in Business Engineering from the University of Liège (1998). He is co-founder of EKLO ASBL, Member of the Executive Committee of Noshaq SA in charge of the Life Sciences sector, CEO of B2H SA, the public company superseding the Liege life sciences ecosystem, and Investment Manager of Epimede SA, a EUR 50 million Belgian based private high-tech growth fund. He has more than 15 years of experience in strategic consulting and investment at all stages of development of small and medium high tech- high growth life sciences enterprises. He played a key role in several financing rounds at critical development stages of various Belgian young biotech companies among which: Mithra Pharmaceuticals SA, Imcyse SA, Uteron Pharma SA, PDC Line Pharma SA, Diagenode SA. As an entrepreneur, Marc Foidart is Co-Founder and past CEO of Arlenda SA, a spin-off company of the University of Liège providing expert statistical solutions to the pharmaceutical, chemical and environment industries. He is
also Co-Founder and Executive Chairman of Eyed Pharma SA, a start-up company developing innovative controlled release microimplants in ophthalmology. Marc Foidart has been associate professor at the University of Liege since 2011.
Carolyn Myers
INDEPENDENT DIRECTOR
mble Ltd, a business strategy consulting firm that advises C-suite executives of small and medium size companies on a comprehensive range of drug development, commercial and business development services. Carolyn’s experience comes from having led many businesses in their growth strategies. At Allergan (formerly Actavis), she was the Vice President of Global Business Development and Alliance Management with a focus on expanding product portfolios. At Forest Laboratories (acquired by Actavis), Carolyn was the Vice President of the CNS marketing group responsible for marketing and sales of established and new products. At Mylan she held two different leadership positions including
President of Mylan Technologies, a division focused on developing generic transdermal systems and President of Dey Laboratories having full P&L responsibility to develop, manufacture and sell innovative respiratory products. Carolyn is also an advisor to several start-up organizations and capital investors.
Carolyn earned a PhD in Genetics from the University of British Columbia and an MBA from Rutgers University.
James Gale
INDEPENDENT DIRECTOR
James (Jim) Gale is the founding partner of Signet Healthcare Partners. Jim has over 30 years of healthcare investing and finance experience.
Jim is a Managing Director in Signet Fund IV and is currently the Chairman of the Board of Alpex Pharma S.A., Knight Therapeutics Inc. (TSX: GUD), Teligent (NSDQ: TLGT, formerly IGI Laboratories), and also serves on the Board of Directors of Bionpharma, Chr. Olesen Synthesis A/S, CoreRx, LeonNanodrugs GmbH, Pharmaceutics International (Pii), Advantice Health, and RK Pharma. Prior portfolio company boards include Arbor Pharmaceuticals, Amarin Corporation, eResearch Technologies Inc., and Valera Pharmaceuticals.
Prior to founding Signet, Jim was head of principal investment activities and head of investment banking for Gruntal & Co., LLC. While at Gruntal, he made a number of investments including Andrx Corporation, Royce Laboratories (merged with Watson Pharmaceuticals), Lifecell Corporation, Neurocrine Biosciences, and BML Pharmaceuticals (acquired by Endo Pharmaceuticals).
Chris Buyse
INDEPENDENT DIRECTOR
Executive team
Stijn Van Rompay
CHIEF EXECUTIVE OFFICER, CO-FOUNDER AND ACTING CHIEF FINANCIAL OFFICER
Stijn co-founded and was the CEO of Alter Pharma, a high-growth pharmaceutical company focused on the development of complex generics and pharmacy-related product sales. He was also co-CEO of Uteron Pharma, a company focused on innovative female healthcare products.
Prior to these positions, Stijn was CFO and later, CEO of Docpharma (formerly quoted on Euronext Brussels) a generics and medical-device company. Under his leadership, the companies recorded strong growth and value creation. He also holds several non-executive director positions in the biotech sector, and acts as an advisor to venture capital investors. Stijn holds a Master’s degree in Applied Economics from the University of Antwerp.
Thomas Jacobsen
CHIEF BUSINESS DEVELOPMENT OFFICER and CO-FOUNDER
Koenraad Van der Elst
CHIEF LEGAL OFFICER
Koenraad served as General Counsel at Metris (currently Nikon Metrology), and acted as Secretary General & General Counsel of PUNCH INTERNATIONAL, a Belgian company listed on Euronext Brussels. He was also General Counsel & Secretary to the Board of PUNCH GRAPHIX plc, a company listed on the London Stock Exchange (AIM), and President of the Supervisory Board of PUNCH TECHNIX, a company listed on Euronext Amsterdam. Between 1995 and 2002, Koenraad was the Director of Legal Documentation at the Investment Banking Department (corporate finance & capital markets) of Generale Bank/Fortis Bank and was involved in most capital market transactions in Belgium (take-over bids, exchange offers, initial public offerings, etc.), as well as in a large number of corporate finance deals (M&A, advisory, fairness opinions, mergers, restructurings, etc.), at local, cross-border and international levels.
In addition, Koenraad was an assistant Professor at the University of Brussels (VUB) in Financial Law. He holds a law degree from the University of Brussels (VUB) and an MBA from EHSAL Brussels.
Dietmar Aichhorn
CHIEF OPERATING OFFICER
Marieke Vermeersch
VP INVESTOR RELATIONS AND CORPORATE COMMUNICATIONS
Marieke holds a Master of Science degree in Bioengineering from the University of Gent and an MBA from Solvay Business School, Brussels.